Lilly Sells $6.5 Billion of Bonds for Cancer Drug Purchase
Eli Lilly & Co. tapped the US investment-grade bond market on Monday to help finance its roughly $2.5 billion purchase of a ...
Eli Lilly to release late-stage data on next-generation weight loss drug retatrutide in 2025, earlier than expected
Eli Lilly expects to provide results from a study in people with obesity and osteoarthritis of the knee in 2025.
Eli Lilly beats on earnings even as weight loss, diabetes drug sales fall short
Eli Lilly reported mixed results for the fourth quarter, even as demand for its blockbuster weight loss drug Zepbound and ...
NBC New York8d
Eli Lilly beats on earnings even as weight loss, diabetes drug sales fall short
Both treatments mimic certain gut hormones to tamp down a person's appetite and regulate their blood sugar. The popularity of those injectable drugs has forced both Eli Lilly and its rival Novo ...
NBC 10 Philadelphia8d
Eli Lilly to release late-stage data on next-generation weight loss drug retatrutide in 2025, earlier than expected
That appears to have more potent effects on a person's appetite and satisfaction with food. Meanwhile, tirzepatide – the active ingredient in Eli Lilly's weight loss shot Zepbound and diabetes ...